{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T03:43:17Z","timestamp":1791603797119,"version":"4.3.4"},"reference-count":51,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T00:00:00Z","timestamp":1778630400000},"content-version":"vor","delay-in-days":12,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["accp1.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Clinical Pharm in Drug Dev"],"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Zampilimab (UCB7858) is a humanized monoclonal immunoglobulin G4P, transglutaminase 2 (TG2) inhibiting antibody. We investigated safety, tolerability, pharmacokinetics, and target occupancy of zampilimab (intravenous \u22642000\u00a0mg; subcutaneous\u00a0\u22641000\u00a0mg) in healthy participants in a randomized, placebo\u2011controlled, single\u2010ascending\u2010dose Phase 1 study (UP0029; NCT02879877). Of 78 participants (58 zampilimab; 20 placebo), treatment\u2010emergent adverse events (TEAEs) occurred in 42 (72.4%) versus 14\u00a0(70%), respectively. One participant (intravenous zampilimab 2000\u00a0mg) reported a serious TEAE of moderate infusion\u2010related reaction (a protocol\u2010defined stopping criterion), leading to a temporary study hold. Although the reaction resolved within 3 days, and the participant completed follow up, dose\u2010escalation was suspended, and the study terminated. Zampilimab demonstrated dose\u2010proportional, linear pharmacokinetics (t\n                    <jats:sub>1\/2<\/jats:sub>\n                    17\u201023 days; subcutaneous bioavailability 77%). TG2 target occupancy in skin directly correlated with serum zampilimab concentration, near\u2010maximal occupancy \u2265250\u00a0\u00b5g\/mL, corresponding to intravenous doses \u22651000\u00a0mg between Days 2 and 5. A subsequent randomized, placebo\u2011controlled, Phase 1 study (UP0105; NCT04705350) investigated single intravenous doses of zampilimab (2000 and 3000\u00a0mg) at a lower concentration and slower infusion rate versus UP0029, using learnings from the administration strategy. Of 16 participants (12 zampilimab; four placebo), TEAEs occurred in eight (66.7%) versus one (25%), respectively. TEAEs were mild\/moderate; none were drug related. No infusion\u2010related reactions occurred. Zampilimab safety profile was acceptable after single intravenous and subcutaneous doses \u22641000\u00a0mg (UP0029) and intravenous doses \u22643000\u00a0mg (UP0105) following optimization of maximum concentration (10\u00a0mg\/mL) at an infusion rate of 25\u00a0mg\/min over 120 min. These studies support the ongoing development of zampilimab.\n                  <\/jats:p>","DOI":"10.1002\/cpdd.70052","type":"journal-article","created":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T14:22:37Z","timestamp":1778682157000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Randomized Phase 1 Studies Evaluating the Safety, Tolerability, Pharmacokinetics, and Target Occupancy of Zampilimab in Healthy Participants"],"prefix":"10.1002","volume":"15","author":[{"given":"Jo","family":"Collier","sequence":"first","affiliation":[{"name":"UCB  Slough UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rowann","family":"Bowcutt","sequence":"additional","affiliation":[{"name":"UCB  Slough UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geoffrey I.","family":"Johnston","sequence":"additional","affiliation":[{"name":"UCB  Slough UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane Y. C.","family":"Chan","sequence":"additional","affiliation":[{"name":"UCB  Slough UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anastasiia","family":"Raievska","sequence":"additional","affiliation":[{"name":"Veramed  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison","family":"Bigley","sequence":"additional","affiliation":[{"name":"OracleBio  Biocity Scotland UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Nicholl","sequence":"additional","affiliation":[{"name":"UCB  Slough UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim S.","family":"Schmidt","sequence":"additional","affiliation":[{"name":"UCB  Slough UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Sarno","sequence":"additional","affiliation":[{"name":"UCB  Slough UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zahid","family":"Ali","sequence":"additional","affiliation":[{"name":"UCB  Slough UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Thomson","sequence":"additional","affiliation":[{"name":"UCB  Slough UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,5,13]]},"reference":[{"key":"e_1_2_12_2_1","doi-asserted-by":"publisher","DOI":"10.1002\/2211-5463.12575"},{"key":"e_1_2_12_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrm1014"},{"key":"e_1_2_12_4_1","doi-asserted-by":"publisher","DOI":"10.1152\/physrev.00019.2013"},{"key":"e_1_2_12_5_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00018-015-1909-z"},{"key":"e_1_2_12_6_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M111.226340"},{"key":"e_1_2_12_7_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00726-008-0190-y"},{"key":"e_1_2_12_8_1","doi-asserted-by":"publisher","DOI":"10.1159\/000078639"},{"key":"e_1_2_12_9_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.ASN.0000079614.63463.DD"},{"key":"e_1_2_12_10_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI119490"},{"key":"e_1_2_12_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2020.107787"},{"key":"e_1_2_12_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-25674-4"},{"issue":"6","key":"e_1_2_12_13_1","first-page":"653","article-title":"Changes in transglutaminase activity in an experimental model of pulmonary fibrosis induced by paraquat","volume":"60","author":"Griffin M","year":"1979","journal-title":"Br J Exp Pathol"},{"key":"e_1_2_12_14_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20101457"},{"key":"e_1_2_12_15_1","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201101-0013OC"},{"key":"e_1_2_12_16_1","doi-asserted-by":"publisher","DOI":"10.1165\/rcmb.2016-0379OC"},{"key":"e_1_2_12_17_1","doi-asserted-by":"publisher","DOI":"10.1165\/rcmb.2021-0012OC"},{"key":"e_1_2_12_18_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41418-017-0028-9"},{"key":"e_1_2_12_19_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-018-0573-2"},{"key":"e_1_2_12_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.dld.2008.12.095"},{"key":"e_1_2_12_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(01)00135-0"},{"key":"e_1_2_12_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.hepres.2004.02.007"},{"key":"e_1_2_12_23_1","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2009.230"},{"key":"e_1_2_12_24_1","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2006070690"},{"key":"e_1_2_12_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/bph.15774"},{"key":"e_1_2_12_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.matbio.2008.10.003"},{"key":"e_1_2_12_27_1","doi-asserted-by":"publisher","DOI":"10.1083\/jcb.136.5.1151"},{"key":"e_1_2_12_28_1","doi-asserted-by":"publisher","DOI":"10.3390\/cells10071842"},{"key":"e_1_2_12_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/0161-5890(93)90432-B"},{"key":"e_1_2_12_30_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0298864"},{"key":"e_1_2_12_31_1","volume-title":"StatPearls","author":"Sankari A","year":"2024"},{"key":"e_1_2_12_32_1","volume-title":"StatPearls","author":"Gole S","year":"2024"},{"key":"e_1_2_12_33_1","volume-title":"StatPearls","author":"Preuss CV","year":"2024"},{"key":"e_1_2_12_34_1","volume-title":"JASCAYD\u00ae (Nerandomilast Tablets), for Oral Use. Prescribing Information","author":"Boehringer Ingelheim Pharmaceuticals, Inc","year":"2025"},{"key":"e_1_2_12_35_1","volume-title":"ESBRIET\u00ae (Pirfenidone) Capsules, for Oral Use. Prescribing Information","author":"InterMune, Inc","year":"2014"},{"key":"e_1_2_12_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2019.105803"},{"key":"e_1_2_12_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(20)30318-0"},{"key":"e_1_2_12_38_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.838449"},{"key":"e_1_2_12_39_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2414108"},{"key":"e_1_2_12_40_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12931-018-0730-2"},{"key":"e_1_2_12_41_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2017.00318"},{"key":"e_1_2_12_42_1","volume-title":"Esbriet\u00ae 267\u00a0mg Film\u2010Coated Tablets. Summary of Product Characteristics","author":"Roche Products Limited","year":"2022"},{"key":"e_1_2_12_43_1","volume-title":"Ofev\u00ae 267\u00a0mg 100\u00a0mg Soft Capsules. Summary of Product Characteristics","author":"Boehringer Ingelheim Limited","year":"2021"},{"key":"e_1_2_12_44_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12882-025-04467-8"},{"key":"e_1_2_12_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.molonc.2014.07.025"},{"key":"e_1_2_12_46_1","doi-asserted-by":"publisher","DOI":"10.1186\/1741-7015-8-18"},{"key":"e_1_2_12_47_1","doi-asserted-by":"publisher","DOI":"10.1096\/fasebj.13.13.1787"},{"key":"e_1_2_12_48_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11882-015-0580-7"},{"issue":"2","key":"e_1_2_12_49_1","first-page":"415","article-title":"Inhibition of complement activation by IgG4 antibodies","volume":"64","author":"Zee JS","year":"1986","journal-title":"Clin Exp Immunol"},{"key":"e_1_2_12_50_1","doi-asserted-by":"publisher","DOI":"10.1188\/10.CJON.E10-E21"},{"key":"e_1_2_12_51_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.1144603"},{"key":"e_1_2_12_52_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2020.102492"}],"container-title":["Clinical Pharmacology in Drug Development"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cpdd.70052","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/cpdd.70052","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cpdd.70052","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T15:27:29Z","timestamp":1787498849000},"score":1,"resource":{"primary":{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/10.1002\/cpdd.70052"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":51,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["10.1002\/cpdd.70052"],"URL":"https:\/\/doi.org\/10.1002\/cpdd.70052","archive":["Portico"],"relation":{},"ISSN":["2160-763X","2160-7648"],"issn-type":[{"value":"2160-763X","type":"print"},{"value":"2160-7648","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"2025-11-13","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-05","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-05-13","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70052"}}